Oligoalanine helical callipers for cell penetration by Pazo Pascual, Marta et al.
1	
Oligoalanine	Helical	Callipers	for	Cell	Penetration	 
Marta Pazo,a Marisa Juanes,a Irene Lostalé-Seijoa & Javier Montenegroa* 
a Centro Singular de Investigación en Química Biolóxica e Materiais Moleculares (CIQUS), Departamento de 


































Materials and methods 
Commercially available Rink Amide-resin ChemMatrix, Fmoc-L-Ala-OH, Fmoc-L-Leu-OH, Fmoc-L-
Arg(pbf)-OH, triisopropylsilane (TIS), Disopropylethyl amine (DIEA), diisopropylcarbodiimide (DIC) 
were obtained from Sigma-Aldrich. Trifluoroethanol, 1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) was 
purchased from TCI. Egg yolk L-α-phosphatidylcholine was purchased from Avanti Polar Lipids. 
Ethyl(hydroxyimino)cyanoacetate (Oxyma) and 5-carboxytetramethyl rhodamine (TAMRA) were 
available from Carbosynth. N-HATU by Glentham life sciences. N-HBTU was obtained from Iris. Peptide 
synthesis grade N,N-dimethylformamide was purchased from Scharlau. Deuterated solvent (D2O) was 
from EMD Millipore Corporation. All the other solvents were HPLC grade, purchased from Sigma-
Aldrich® or Fisher Scientific®, and used without further purification. 
Chlorpromazine was purchased from TCI Chemicals. Ammonium chloride, Chloroquine, Heparin sodium 
salt and 5-(N-Ethyl-N-isopropyl)amiloride were purchased from Sigma-Aldrich. Methyl-β-cyclodextrin 
was purchased from Carbosynth. Hoechst 33342 Trihydrochloride Trihydrate, and LysoTracker Deep Red 
were purchased in ThermoFisher. Wortmannin was obtained from Fluorochem. Dulbecco’s Modified 
Eagle’s Medium (4500 mg/L glucose, L-glutamine, sodium pyruvate and sodium bicarbonate) was 
purchased from Gibco. 
A microwave assisted peptide synthesiser (Liberty Lite, CEM) was used to prepare the peptide according 
to standard methods developed by the manufacturers involving diisopropylcarbodiimide (DIC) 0.5 M in 
DMF as activator and ethyl(hydroxyimino)cyanoacetate (Oxyma) 1 M in DMF as activator base. Previous 
to HPLC, a quick size exclusion chromatography in sephadex G-25 eluted with Milli-Q water was carried 
out to remove the excess of fluorophore. High-performance liquid chromatography coupled with mass 
spectrometry (HPLC-MS) analyses were carried out on Agilent Technologies 1260 Infinity II associated 
with a 6120 Quadrupole LC-MS using an Agilent SB-C18 column or on DIONEX Ultimate 3000 U-
HPLC+ (Thermo Scientific) with an Acclaim RSLC 120-C18 column with Solvent A:Solvent B gradients 
between 5:95 (Solvent A: H2O with 0.1% TFA; Solvent B: CH3CN with 0.1% TFA). High-performance 
liquid chromatography (HPLC) semi-preparative purification was carried out on Jasco LC-4000 with an 
Agilent Eclipse XDB-C18 column.  
Nuclear Magnetic Resonance (NMR) spectra were recorded on a Varian Mercury 300 MHz. Chemical 
shifts are reported in ppm referenced to the following solvent signals: HOD δ H 4.79 ppm. Spin 
multiplicities are reported as a singlet (s), doublet (d), triplet (t) with coupling constants (J) given in Hz, or 
multiplet (m). Accurate mass determinations (HR-MS) using ESI-MS were performed on a Bruker 
MicroTof mass spectrometer. 
Circular Dichroism (CD) measurements were performed with a Jasco J-1100 CD Spectrometer equipped 
with a Jasco MCB-100 Mini Circulation Bath for temperature control.  
For the acquisition of cell microscopy images an Andor Zyla 4.2 digital camera mounted on a Nikon 
Eclipse Ti-E epifluorescence microscope was used, and to do the images in 3D a Dragonfly confocal 
spinning-disk on a Nikon Eclipse Ti-E equipped with a Andor Zyla 4.2 PLUS sCMOS digital camera. The 
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3D projection was obtained from the different individual confocal planes with Imaris bitplane © 9.0.0 
software.	
A Tecan Infinite F200Pro microplate reader was used to measure directly in Costar cell culture 96-well 
plates UV-Vis absorbance for the MTT viability assays. 
Flow cytometry was performed on a Guava easyCyteTM cytometer. Data analysis was performed with 
InCyte software included in GuavaSoft 3.2 (Millipore). 
Abbreviations 
Aa: Amino acid; Arg: Arginine; Calcd: Calculated; CLQ: Chloroquine; CPZ: Chlorpromazine; DCM: 
Dichloromethane; DIC: diisopropylcarbodiimide; DIEA: N,N-Diisopropylethylamine; DMF: N,N-
Dimethylformamide; DYN: Dynasore; EIPA: 5-(N-Ethyl-N-isopropyl)amiloride; EYPC: Egg yolk 
phosphatidylcholine; Hep: Heparin sodium salt; HFIP: 1,1,1,3,3,3-Hexafluoro-2-propanol; HRMS (ESI): 
High resolution mass spectrometry (electrospray ionization); Leu: Leucine; Lys: Lysine; MbCD: Methyl-
beta-Cyclodextrin; Mtt: 4-Methyltrytil; N-HATU:N-[(Dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridine-
1ylmethylene]-N-methylmethanaminium-hexafluorophosphate N-oxide; N-HBTU: N-[(1HBenzotriazol-1-
yl)-(dimethylamino)methylene]-N-methylmethanaminium hexafluorophosphate N-oxide; Pbf: 2,2,4,6,7-
Pentamethyldihydrobenzofuran-5-sulfonyl; SPC: spacer; SPPS: solid phase peptide synthesis; TAMRA: 5-
carboxytetramethyl rhodamine; TFE: Trifluoroethanol; TNBS: 2,4,6-Trinitrobenzenesulfonic acid; TIS: 
Triisopropylsilane; W: Wortmannin; 6Ahx: 6-aminohexanoic acid. 
 
General protocols 
General protocol for the SPPS 
All peptides were synthesized by automated or manual Fmoc solid-phase peptide synthesisS1 using Rink 
Amide ChemMatrix resin (loading 0.5 mmol/g). For manual synthesis, the resin (0.5 mmol) was swelled in 
DMF (peptide synthesis grade, 2 mL) for 20 min in a peptide synthesis vessel prior synthesis. Coupling 
cycle consisted of the removal of Fmoc protecting group with a solution of piperidine in DMF (20%, 2 
mL) for 10 min and then the mixture was filtered and the resin was washed with DMF (3 x 2 mL, 1 min). 
The amino acid coupling was carried out by treatment with a solution of α-amino acids (4 equiv.), N-
HBTU (3.95 equiv.) in DMF (2 mL), which was mixed with DIEA (0.195 M solution in DMF, 1.2 equiv.) 
1 min before the addition and the resulting mixture was shaken by bubbling Ar for 15 min. Finally, the 
resin was washed with DMF (3 x 2 mL, 1 min). The efficiency of each amino acid coupling and 
deprotection was monitored employing the TNBS test.S2 
For automated synthesis, a variant of the previous protocol was used instead, according to manufacturer’s 
recommendations. 0.05 mmol of Rink Amide resin was placed into the peptide synthesiser reaction vessel, 
swollen in DMF, followed by cycles of Fmoc cleavage with piperidine 20% in DMF, washings (3 x 5 mL), 
then amino acid (5 equiv. 2M amino acid solution in DMF), DIC (10 equiv.) and Oxyma (10 equiv.) were 
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added into the reaction vessel and microwaved for 5 min under temperature control followed by washings 
(3 x 5 mL). All steps were performed under nitrogen atmosphere. After the linear peptide was finished the 
resin was transferred to a different reaction vessel to perform the peptide modification manually. 
A) Linker coupling: after Fmoc cleavage with piperidine/DMF (20%, 2 mL), the linear peptide was 
treated with a solution of N-Fmoc-6-aminohexanoic acid (4 equiv.), N-HBTU (3.95 equiv.) and DIEA 
(0.195 M solution in DMF, 1.2 equiv.) in DMF. 
B) Fluorophore coupling: the Fmoc-protecting group of the lineal final peptide (or the previously 
attached linker) was removed by using a solution of piperidine in DMF (20%, 4 mL) for 15 min and 
the resin was washed with DMF (3 x 3 mL). The coupling was carried out by the addition of a 
solution of 5-Carboxytetramethylrhodamine (1 equiv.), HATU (1 equiv.), and DIEA (0.195 M, 1 
equiv.) in DMF (2 mL) and the mixture was stirred by bubbling Ar for 4 hours. Finally, the resin was 
washed with DMF (3 x 3 mL) and DCM (3 x 3 mL). 
General protocol for peptide cleavage and purification 
Finally, peptides were deprotected and cleaved from the resin by standard TFA cleavage procedure at rt by 
using the TFA/DCM/H2O/TIS (90:5:2.5:2.5, 3 mL per 70 mg of resin) for 2 h. Then, the mixture was 
filtered, washed with TFA (1 mL) and the peptide was precipitated with ice-cold Et2O (50 mL). The 
precipitate was centrifuged and dissolved in H2O (5 mL). 
Peptides were purified first with sephadex size exclusion chromatography (G-25, Milli-Q water) and then 
by semi-preparative high-performance liquid chromatography (HPLC) as previously described. Finally, the 
corresponding fractions were lyophilised to afford the pure peptide as pink solids. 
Synthesis of peptide P1 
Following the general protocol of the SPPS followed by fluorophore coupling, P1 was obtained after RP-
HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 12%. Rt 13.0 min [RP-HPLC 
Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] (Fig. S12). MS 
(ESI, H2O): 911.9 (35, [M+2H]2+), 608.3 (100, [M+3H]3+), 456.5 (35, [M+4H]4+). HRMS (ESI): Calcd for 
C82H126N28O20 [M+2H]2+: 911.4846; found: 911.4839. 
Synthesis of peptide P2 
Following the general protocol of the SPPS followed by fluorophore coupling, P2 was obtained after RP-
HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 10.7%. Rt 14.6 min [RP-HPLC 
Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] (Fig. S13). MS 
(ESI, H2O): 953.9 (40, [M+2H]2+), 636.3 (100, [M+3H]3+), 477.6 (35, [M+4H]4+). HRMS (ESI): Calcd for 
C88H138N28O20 [M+2H]2+: 953.5317; found: 953.5316. 
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Synthesis of peptide P3*  
Following the general protocol of the SPPS followed by linker and fluorophore coupling, P3* was obtained 
after RP-HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% 
TFA) 95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 8.7%. Rt 14.2 min. [RP-
HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] (Fig. 
S14). MS (ESI, H2O): 1088.8 (5, [M+2H+TFA]2+), 1031.4 (35, [M+2H]2+), 688.0 (100, [M+3H]3+), 516.3 
(40, [M+4H]4+). HRMS (ESI): Calcd for C97H155N29O21 [M+2H]2+: 1031.0976; found: 1031.0971. 
Synthesis of peptide P4 
Following the general protocol of the SPPS followed by fluorophore coupling, P4 was obtained after RP-
HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 6.5%. Rt 14.9 min [RP-HPLC 
Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] (Fig. S15). MS 
(ESI, H2O): 975.0 (70, [M+2H]2+), 650.3 (100, [M+3H]3+), 488.0 (15, [M+4H]4+). HRMS (ESI): Calcd for 
C91H144N28O20 [M+2H]2+: 974.5551; found: 974.5550. 
Synthesis of peptide P5* 
Following the general protocol of the SPPS followed by linker and fluorophore coupling, P5* was obtained 
after RP-HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% 
TFA) 95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 2.9%. Rt 15.2 min [RP-
HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] (Fig. 
S16). MS (ESI, H2O): 1031.4 (38, [M+2H]2+), 688.0 (100, [M+3H]3+), 516.3 (55, [M+4H]4+). HRMS 
(ESI): Calcd for C97H155N29O21 [M+2H]2+: 1031.0976; found: 1031.0886. 
Synthesis of peptide P6* a) and P7 b) 
a) Following the general protocol of the SPPS followed by linker and fluorophore coupling, P6* was 
obtained after RP-HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN 
(0.1% TFA) 95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 6.4%. Rt 15.2 min 
[RP-HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] 
(Fig. S17). MS (ESI, H2O): 1031.4 (40, [M+2H]2+), 688.0 (100, [M+3H]3+), 516.3 (50, [M+4H]4+). HRMS 
(ESI): Calcd for C97H155N29O2 [M+2H]2+: 1031.0976; found: 1031.097. 
b) Following the general protocol of the SPPS followed by fluorophore coupling, P7 was obtained after 
RP-HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 5.3%. Rt 15.5 min [RP-HPLC 
Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] (Fig. S18). MS 
(ESI, H2O): 974.8 (50, [M+2H]2+), 650.3 (100, [M+3H]3+), 488.1 (30, [M+4H]4+). HRMS (ESI): Calcd for 
C91H144N28O20 [M+2H]2+: 974.5544; found: 974.5550. 
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Synthesis of peptide P8 
Following the general protocol of the SPPS followed by fluorophore coupling, P8 was obtained after RP-
HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
95:5→5:95 (0→5 min), 95:5→5:95 (5→35 min)] with an overall yield of 1.7%. Rt 15.2 min [RP-HPLC 
Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20 min)] (Fig. S19). MS 
(ESI, H2O): 974.8 (40, [M+2H]2+), 650.3 (100, [M+3H]3+), 488.1 (23, [M+4H]4+). 1H NMR (300 MHz, 
D2O) δ 8.53-8.45 (m, 1H), 8.18-8.10 (m, 1H), 7.57-7.47 (m, 1H), 7.21-7.10 (m, 2H), 6.96-6.86 (m, 2H), 
6.68 (s, 2H), 4.38-4.15 (m, 16H), 3.30-3.10 (m, 18H), 1.94-1.59 (m, 22H), 1.55-1.35 (m, 30H), 1.05-0.84 
(m, 18H). HRMS (ESI): Calcd for C91H144N28O20 [M+2H]2+: 974.5555; found: 974.5550. 
Synthesis of peptide R8 
Following the general protocol of the SPPS followed by fluorophore coupling, R8 was obtained after RP-
HPLC purification [Phenomenex Luna C18(2) 100A column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 
100:0→100:0 (0→5 min), 50:50→50:50 (5→35 min)] with an overall yield of 1.7%. Rt 11.4 min (Fig. 
S20) [RP-HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 (0→20min). 
MS (ESI, H2O): 1067.7 (19, [M+2H+3TFA]2+), 1010.8 (10, [M+2H+2TFA]2+), 712.2 (45, 
[M+3H+3TFA]3+), 674.2 (100, [M+3H+2TFA]3+), 636.5 (75, [M+3H+TFA]3+), 598.2 (20, [M+3H]3+), 
477.5 (40, [M+4H+TFA]4+), 448.9 (30, [M+4H]4+), 359.4 (27, [M+5H]5+). HRMS (ESI): Calcd for 
C79H131N36O13 [M+H]+: 1792.0679; found: 1792.0691. 
General protocol to measure Circular Dichroism 
Circular dichroism measurements were carried out with the following settings: acquisition range: 300-190 
nm; band width: 1.0 nm; accumulation: 3 scans; data pitch: 1 nm; CD scale 200 mdeg/1.0 dOD; D.I.T. 
(Data Integration Time): 1 s; scanning mode: continuous; scanning speed: 200 nm/min. Measurements 
were done from 10 ºC to 60 ºC (data interval: 10 ºC; temp. gradient 5 ºC/min) in a quartz cell of 0.2 cm 
path length at a final volume of 0.5 mL (H2O or TFE) with a final peptide concentration of 100 µM. The 
results are expressed as the mean residue molar ellipticity [θ]MRt with units of degrees·cm2·dmol-1 and 
calculated using the equation S1. The percentage of helicity was calculated using the equation S2. For the 
measurements in liposomes, samples were prepared by drying under reduced pressure L-α-
phosphatidylcholine (16.7 µL, 25 mg/mL solution in CHCl3) and peptide (300 µL, 100µM) in TFE to 
obtain a ratio lipid/peptide of 18:1 in a 10 mL round bottomed flask. The mixture was concentrated in a 
rotary evaporator to dryness, forming a film. The lipid/peptide mixture were suspended in HKR buffer 
(300 µL) to a final peptide concentration 100 µM and sonicated for 45 min until a clear solution was 
obtained. Spectra were recorded in a 0.2 cm path length quartz cell.S3 
[Ɵ]MRt =
!.! ! Ɵ
!· !· !"#$%& !" !"#$%&"#
   (deg · cm2 · dmol -1) 
Equation S1: Formula to calculate the ellipticity. Ɵ is the ellipticity (mdeg), C is the peptide concentration 
(M) and l is the cell path length (cm). 
(S1) 
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Equation S2: Formula to calculate the percent of helicity in where the molar ellipticity at 222 nm is an 
absolute value. 
Cell assays 
Cell culture and live cell imaging  
HeLa cells were grown at 37 ºC, 5% CO2, in Dulbecco’s Modified Eagle’s Medium (4500 mg/L glucose, 
L-glutamine, sodium pyruvate and sodium bicarbonate; SigmaAldrich), supplemented with 10% fetal 
bovine serum (Sigma-Aldrich) and 1% of Penicillin-Streptomycin-Glutamine Mix.  
SF9 Cells were grown at 28 ºC, in mechanical stirring, in Gibco Sf-900-II medium, complemented with 
10% fetal bovine serum (Sigma-Aldrich) and 1% of Penicillin-Streptomycin-Glutamine Mix. 
A-549 cells were grown at 37 ºC, 5% CO2, in Dulbecco’s Modified Eagle’s Medium (4500 mg/L glucose, 
L-glutamine, sodium pyruvate and sodium bicarbonate; SigmaAldrich), supplemented with 10% fetal 
bovine serum (Sigma-Aldrich) and 1% of Penicillin-Streptomycin-Glutamine Mix.  
For live cell imaging, HeLa cells grown on glass bottom dishes were washed with HEPES-Krebs-Ringer 
(HKR) buffer (5 mM HEPES, 137 mM NaCl, 2.68 mM KCl, 2.05 mM MgCl2, 1.8 mM CaCl2, pH 7,4) and 
incubated for 30 min with 1 µM Hoechst 33342 (ThermoFisher) in HKR to stain the nucleus. This solution 
was removed and cells were incubated for another 30 min with 0.5; 1; 3; 5 µM of each peptide diluted in 
HKR buffer, washed twice with HKR and examined on an epifluorescence microscope (Nikon Eclipse Ti-
E). 
For live cell imaging, SF9 cell grown on glass bottom dishes were washed with Sf-900-II medium 
incubated for 30 min with 1 µM Hoechst 33342 (ThermoFisher) in Sf-900-II to stain the nucleus. This 
solution was removed and cells were incubated for another 30 min with 1; 3; 5; 7 µM of each (Peptides) 
diluted in Sf-900-II medium, washed twice with Sf-900-II and examined on an epifluorescence microscope 
(Nikon Eclipse Ti-E). 
For live cell imaging, A-549 cells grown on glass bottom dishes were washed with HEPES-Krebs-Ringer 
(HKR) buffer (5 mM HEPES, 137 mM NaCl, 2.68 mM KCl, 2.05 mM MgCl2, 1.8 mM CaCl2, pH 7.4) and 
incubated for 30 min with 1 µM Hoechst 33342 (ThermoFisher) in HKR to stain the nucleus. This solution 
was removed and cells were incubated for another 30 min with 0.5; 1; 3; 5 µM of each peptide diluted in 
HKR buffer, washed twice with HKR and examined on an epifluorescence microscope (Nikon Eclipse Ti-
E). 
Quantification of the uptake by flow cytometry 
For internalization standard assays, we measured the amount of peptide by flow cytometry. Briefly, 
semiconfluent monolayers of HeLa cells seeded the day before were washed twice with HKR before 
incubation with different concentrations (1, 3, 5, 7, 10 µM) of TAMRA labelled peptides for 1 hour at 37 
(S2) 
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ºC. Then, cells were trypsinized to remove membrane bound peptidesS4,S5 and to prepare the samples for 
flow cytometry using 100 µL of Trypsin-EDTA (Gibco) for 10 min at 37 ºC, and trypsin neutralized with 
100 µL of 2% FBS in PBS with 5 mM EDTA. Pipetting broke cell clumps and the analysis was done in a 
Guava easyCyteTM cytometer. TAMRA levels were determined by excitation at 532 nm and detection at 
575/25 nm. For the analysis, cells with typical FSC and SSC parameters were selected, and median 
fluorescence intensity was calculated for each sample. Data analysis was performed with InCyte software 
included in GuavaSoft 3.2 (Millipore). 
Quantification of inhibition the uptake by flow cytometry 
To study the cellular uptake mechanisms, HeLa cells growing in a 96 well plate (100.000 cells per well 
seeded) were treated for 30 min with the following compounds diluted in DMEM without serum or 
antibiotics: Dynasore (80 µM), chlorpromazine (30 µM), methyl-β-cyclodextrin (5 mM), Wortmannin (200 
nM), EIPA (50 µM), heparin (5 µg/mL), chloroquine (100 µM) or ammonium chloride (50 mM). For the 
incubation at low temperature, another plate was incubated on ice and ice-cold solutions were used for the 
washes and incubations. Cells were then incubated with the TAMRA-labelled peptides in the presence of 
the same amount of inhibitors in DMEM for 30 min at 37 ºC. Cells were washed twice with HKR and 0.1 
mg/mL of heparin in HKR and trypsinized. Trypsin was neutralized with 2% FBS in PBS with 5 mM 
EDTA and cell fluorescence was measured on a Guava EasyCyteTM cytometer using a green laser (532 nm) 
and collecting the emission at 575/25 nm. Cells with typical FSC and SSC parameters were selected and 
the median fluorescence intensity calculated for each sample (MFI). Each condition was done in triplicate. 
In the study of the uptake inhibition at different concentrations of the peptide, fluorescence values were 
normalized to the uptake of each untreated control (100%) after blank subtraction. In all cases, data 
analysis was performed with InCyte software included in GuavaSoft 3.2 (Millipore). 
Cell viability  
Cell viability was established by a standard MTT assay. One day before the assay, a suspension of HeLa 
cells was plated in 96-well tissue culture plates (Costar 96 Flat Bottom Transparent Polystyrol) by adding 
100 µl (∼10.000 cells) per well. The next day, the medium was aspirated and cells were incubated in 
DMEM containing 10% Fetal Bovine Serum (FBS) in the presence of the different peptides (50 µl/well) at 
different concentrations (1, 3, 4, 5, 7, 10 µM). After 1 h of incubation at 37 ºC, the viability was measured 
by quantifying the cellular ability to reduce the water-soluble tetrazolium dye 3-4,5-dimethylthiazole-2,5-
diphenyl tetrazolium bromide (MTT) to its insoluble formazan salt as follows. MTT (5 mg/ml in PBS, 10 
µl/well) was added to the wells and the cells were further incubated for 4 h. The supernatant was carefully 
removed and the water-insoluble formazan salt was dissolved in DMSO (100 µl/well). The absorbance at 
570 nm was measured. Data points were collected in triplicate and expressed as normalized values for 




Peptide stability in serum 
To determine the half-life of P8 in serum, the peptide was dissolved in FBS at a final concentration of 100 
µM and incubated at 37 ºC. At different time points, 40 µL aliquots were taken. Samples were mixed with 
an equal volume of acetonitrile and centrifuged for 5 min at 10000 rpm to remove most serum proteins. 
Supernatants were freeze-dried and resuspended in 50 µL Milli-Q water, before quantitation by HPLC, 
measuring TAMRA absorbance at 555 nm [RP-HPLC Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN 











Figure S2: A) Heptad structures of the peptides ordered by increased helicity in liposomes. B) Circular 
dichroism in HKR buffer, liposomes and TFE (from left to right) of all peptides. The measurements were 
taken at different temperatures (10-60 oC). All samples were at 100 µM peptide final concentration. 
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Figure S3: Epifluorescence image of peptides in HeLa cells. P1, P2, P3*, P4 and P5*. DIC on the left and merge channels (peptide and nuclei) on the right. HeLa cells 
were treated first with Hoechst 33342 for 30 min, washed (HKR buffer, 1x) and then incubated with the peptides (0.5, 1, 3 and 5 µM) in HKR buffer for 30 min. The 
cells were finally washed (HKR buffer, 3x) and then observed with the epifluorescence microscope. 
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Figure S4: Epifluorescence image of peptides in HeLa cells. P6 in HeLa cells; P7 in HeLa cells; P8 in HeLa cells; P8 in A-549 cells; P8 in SF9 cells. DIC on the left and 
merge channels (peptide and nuclei) on the right. HeLa cells were treated first with Hoechst 33342 for 30 min, washed (HKR buffer, 1x) and then incubated with the 
peptides (0.5, 1, 3 and 5 µM) in HKR buffer for 30 min. The cells were finally washed (HKR buffer, 3x) and then observed with the epifluorescence microscope. In the 






Figure S5: LysoTracker colocalization studies. HeLa cells and A549 cells were incubated with 5 µM P8 peptide for 30 min in HKR, washed and incubated with 
DMEM with 10 % serum for 3 h. Lysosomes were stained with 50 nM LysoTracker Deep Red the last 30 min of incubation before imaging in a confocal microscope. 









Figure S6: A) Histogram of the uptake in relative fluorescence units (RFU) for P8 (5 µM) in the presence 
of different endocytic inhibitors. In the histogram, the green column is the peptide alone, and the blue 
columns are the uptake in the presence of the inhibitors: 4ºC, CPZ: chlorpromazine; NH4Cl: Ammonium 
Chloride; W: Wortmannin; EIPA: 5-(N-Ethyl-N-isopropyl)amiloride; CLQ: chloroquine; DYN: 
Dynasore; MβCD: methyl-β-cyclodextrin; Hep: heparin. Error bars indicate SD of three replicates. Hela 
cells were treated in DMEM (-) for 30 min prior to trypsinization and cytometry quantification. B) Study 
of the endocytic mechanism at different peptide concentrations. HeLa cells were treated with the 
indicated inhibitors for 30 min in DMEM (-) before incubating with the peptide P8 at different 
concentrations for 30 min. Cells were then trypsinized and analyzed by flow cytometry. Error bars 






















Figure S7: Uptake quantification by flow cytometry of the peptide P8 in three different cell lines: HeLa 
cells in blue, A-549 cells in red and SF9 cells in green. The points were collected at six different 
concentrations (0, 1, 3, 5, 7, 10 µM). Cells were treated in DMEM (-) or Sf-900-II in the case of Sf9 cells 






















                                   
  	  
    
              
 
   
 





















































































































	 	 	 	
Figure S9: MTT assay at different concentrations of peptide P8 in three different cell lines: HeLa, A-549, SF9 and R8 in HeLa cells. Hela cells were treated in DMEM 










































































Figure S10: MTT assay at increasing concentrations of P8 in HeLa cells. Cells were incubated for 1 h with 
the peptide in DMEM (-) before MTT assay. Curve fitting was done with KaleidaGraph software, using a 4-
parameters logistic model. IC50 = 9.2 µM. 
 
 
Figure S11: Stability in the presence of serum. A) A-549 and HeLa cells were incubated for 30 min with 5 
µM disolved in DMEM (-) or DMEM supplemented with 10 % FBS. Cells were then washed three times with 
DMEM (-) and imaged in a confocal microscope. B) RP-HPLC of P8 after different incubation times with 
FBS (555 nm absorbance) C) Calculation of P8 half-life in serum. Area of the peak corresponding to the intact 
peptide was measured for all the time points and normalized to time 0 h (100 %). Data was adjusted to an 
exponential decay curve using KaleidaGraph. P8 half-life ~ 2.2 h. 	 	
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Supporting figures of Characterization 
 
Figure S12: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 




Figure S13: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 
(0→20 min)] (Rt 14.6 min) absorbance at 222 nm and 555 nm and ESI-MS for Peptide P2. 
 
Figure S14: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 
(0→20 min)] (Rt 14.2 min) absorbance at 222 nm and 555 nm and ESI-MS for Peptide P3*.
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Figure S15: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 
(0→20 min)] (Rt 14.9 min) absorbance at 222 nm and 555 nm and ESI-MS for Peptide P4. 
 
Figure S16: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 
(0→20 min)] (Rt 15.2 min) absorbance at 222 nm and 555 nm and ESI-MS for Peptide P5*. 
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Figure S17: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 
(0→20 min)] (Rt 15.3 min) absorbance at 222 nm and 555 nm and ESI-MS for Peptide P6*. 
 
Figure S18: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 




Figure S19: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 




Figure S20: RP-HPLC [Agilent SB-C18 column, H2O (0.1% TFA)/ CH3CN (0.1% TFA) 95:5→5:95 
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